Abbott Biotechnology Ltd.

Basf Aktiengesellschaft

Medical Research Council

Abbvie Biotechnology Ltd

Cambridge Antibody Technology Limited

Deborah J Allen

Boris Labkovsky

Tristan J Vaughan

Jochen G Salfeld

Zehra Kaymakcalan

Michael White

Brian Timothy McGuinness

Paul Sakorafas

John A Mankovich

David Schoenhaut

Andrew J Roberts

Alison Jane Wilton

Hendricus R J M Hoogenboom

John Gerald McCafferty

Hendricus Renerus Hoogenboom

Alison J Wilton

Hendricus Rjm Hoogenboom

Jane Katharine Osbourne

Hendricus R Hoogenboom

Brian T Mcguinness

Boris Labkovksy

Hendricus RJM Hoogenboom

Brian T Mcguiness

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &#x3b1; (hTNF&#x3b1;) are disclosed. These antibodies have high affinity for hTNF&#x3b1; (e.g., K=10M or less), a slow off rate for hTNF&#x3b1; dissociation (e.g., K=10secor less) and neutralize hTNF&#x3b1; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&#x3b1; and for inhibiting hTNF&#x3b1; activity, e.g., in a human subject suffering from a disorder in which hTNF&#x3b1; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human TNF&#x3b1;

Human antibodies that bind human TNF&#x3b1; and methods of using same

Methods of treating disorders using human antibodies that bind human TNF&#x3b1;

Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa

Methods for treating rheumatoid arthritis using human antibodies that bind human TNF&#x3b1;

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor a (hTNF&#x3b1;) are disclosed. These antibodies have high affinity for hTNF&#x3b1; (e.g., K=10M or less), a slow off rate for hTNF&#x3b1; dissociation (e.g., K=10secor less) and neutralize hTNF&#x3b1; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&#x3b1; and for inhibiting hTNF&#x3b1; activity, e.g., in a human subject suffering from a disorder in which hTNF&#x3b1; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &agr; (hTNF&agr;) are disclosed. These antibodies have high affinity for hTNF&agr; (e.g., K &equals;10 M or less), a slow off rate for hTNF&agr; dissociation (e.g., K &equals;10 sec or less) and neutralize hTNF&agr; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&agr; and for inhibiting hTNF&agr; activity, e.g., in a human subject suffering from a disorder in which hTNF&agr; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human TNFa

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &agr;(hTNF&agr;) are disclosed. These antibodies have high affinity for hTNF&agr; (e.g., K,&equals;10,M or less), a slow off rate for hTNF&agr; dissociation (e.g., K,&equals;10,sec,or less) and neutralize hTNF&agr; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF&agr; and for inhibiting hTNF&agr; activity, e.g., in a human subject suffering from a disorder in which hTNF&agr; activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human TNF&agr;

Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. These antibodies have high affinity for hTNF.alpha. (e.g., K.sub.d =10.sup.-8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., K.sub.off =10.sup.-3 sec.sup.-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF.alpha. and for inhibiting hTNF.alpha. activity, e.g., in a human subject suffering from a disorder in which hTNF.alpha. activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Human antibodies that bind human TNF.alpha.

Specific binding members for human carcinoembryonic antigen (CEA) comprise a human antibody antigen binding domain. The specific binding members may have a dissociation constant less than 1.0.times.10.sup.-8 M and may be substantially non-crossreactive with human liver and/or other normal tissues. They may be specific for the A3-B3 extracellular domain of CEA. They may be specific for a carbohydrate epitope of CEA. They may be produced by recombinant expression from encoding nucleic acid and modified and manipulated in various manners in accordance with known techniques. CEA is a tumour antigen and the specific binding members have proven ability to bind and target CEA both in vitro and in vivo.

Specific binding members, materials and methods

Growing community of inventors

London, United Kingdom

Deborah J Allen